Multiple Acyl-Coa Dehydrogenase Deficiency
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hyperammonemia in Review: Pathophysiology, Diagnosis, and Treatment
Pediatr Nephrol DOI 10.1007/s00467-011-1838-5 EDUCATIONAL REVIEW Hyperammonemia in review: pathophysiology, diagnosis, and treatment Ari Auron & Patrick D. Brophy Received: 23 September 2010 /Revised: 9 January 2011 /Accepted: 12 January 2011 # IPNA 2011 Abstract Ammonia is an important source of nitrogen and is the breakdown and catabolism of dietary and bodily proteins, required for amino acid synthesis. It is also necessary for respectively. In healthy individuals, amino acids that are not normal acid-base balance. When present in high concentra- needed for protein synthesis are metabolized in various tions, ammonia is toxic. Endogenous ammonia intoxication chemical pathways, with the rest of the nitrogen waste being can occur when there is impaired capacity of the body to converted to urea. Ammonia is important for normal animal excrete nitrogenous waste, as seen with congenital enzymatic acid-base balance. During exercise, ammonia is produced in deficiencies. A variety of environmental causes and medica- skeletal muscle from deamination of adenosine monophos- tions may also lead to ammonia toxicity. Hyperammonemia phate and amino acid catabolism. In the brain, the latter refers to a clinical condition associated with elevated processes plus the activity of glutamate dehydrogenase ammonia levels manifested by a variety of symptoms and mediate ammonia production. After formation of ammonium signs, including significant central nervous system (CNS) from glutamine, α-ketoglutarate, a byproduct, may be abnormalities. Appropriate and timely management requires a degraded to produce two molecules of bicarbonate, which solid understanding of the fundamental pathophysiology, are then available to buffer acids produced by dietary sources. differential diagnosis, and treatment approaches available. -
Leading Article the Molecular and Genetic Base of Congenital Transport
Gut 2000;46:585–587 585 Gut: first published as 10.1136/gut.46.5.585 on 1 May 2000. Downloaded from Leading article The molecular and genetic base of congenital transport defects In the past 10 years, several monogenetic abnormalities Given the size of SGLT1 mRNA (2.3 kb), the gene is large, have been identified in families with congenital intestinal with 15 exons, and the introns range between 3 and 2.2 kb. transport defects. Wright and colleagues12 described the A single base change was identified in the entire coding first, which concerns congenital glucose and galactose region of one child, a finding that was confirmed in the malabsorption. Subsequently, altered genes were identified other aZicted sister. This was a homozygous guanine to in partial or total loss of nutrient absorption, including adenine base change at position 92. The patient’s parents cystinuria, lysinuric protein intolerance, Menkes’ disease were heterozygotes for this mutation. In addition, it was (copper malabsorption), bile salt malabsorption, certain found that the 92 mutation was associated with inhibition forms of lipid malabsorption, and congenital chloride diar- of sugar transport by the protein. Since the first familial rhoea. Altered genes may also result in decreased secretion study, genomic DNA has been screened in 31 symptomatic (for chloride in cystic fibrosis) or increased absorption (for GGM patients in 27 kindred from diVerent parts of the sodium in Liddle’s syndrome or copper in Wilson’s world. In all 33 cases the mutation produced truncated or disease)—for general review see Scriver and colleagues,3 mutant proteins. -
Inherited Metabolic Disease
Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal -
Novel Insights Into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2017 Novel Insights into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria Schumann, Anke Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-148531 Dissertation Published Version Originally published at: Schumann, Anke. Novel Insights into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria. 2017, University of Zurich, Faculty of Medicine. Novel Insights into the Pathophysiology of Kidney Disease in Methylmalonic Aciduria Dissertation zur Erlangung der naturwissenschaftlichen Doktorwürde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultät der Universität Zürich von Anke Schumann aus Deutschland Promotionskommission Prof. Dr. Olivier Devuyst (Vorsitz und Leitung der Dissertation) Prof. Dr. Matthias R. Baumgartner Prof. Dr. Stefan Kölker Zürich, 2017 DECLARATION I hereby declare that the presented work and results are the product of my own work. Contributions of others or sources used for explanations are acknowledged and cited as such. This work was carried out in Zurich under the supervision of Prof. Dr. O. Devuyst and Prof. Dr. M.R. Baumgartner from August 2012 to August 2016. Peer-reviewed publications presented in this work: Haarmann A, Mayr M, Kölker S, Baumgartner ER, Schnierda J, Hopfer H, Devuyst O, Baumgartner MR. Renal involvement in a patient with cobalamin A type (cblA) methylmalonic aciduria: a 42-year follow-up. Mol Genet Metab. 2013 Dec;110(4):472-6. doi: 10.1016/j.ymgme.2013.08.021. Epub 2013 Sep 17. Schumann A, Luciani A, Berquez M, Tokonami N, Debaix H, Forny P, Kölker S, Diomedi Camassei F, CB, MK, Faresse N, Hall A, Ziegler U, Baumgartner M and Devuyst O. -
Summary Current Practices Report
18/10/2011 EU Tender “Evaluation of population newborn screening practices for rare disorders in Member States of the European Union” Short Executive Summary of the Report on the practices of newborn screening for rare disorders implemented in Member States of the European Union, Candidate, Potential Candidate and EFTA Countries Authors: Peter Burgard1, Martina Cornel2, Francesco Di Filippo4, Gisela Haege1, Georg F. Hoffmann1, Martin Lindner1, J. Gerard Loeber3, Tessel Rigter2, Kathrin Rupp1, 4 Domenica Taruscio4,Luciano Vittozzi , Stephanie Weinreich2 1 Department of Pediatrics , University Hospital - Heidelberg (DE) 2 VU University Medical Centre - Amsterdam (NL) 3 RIVM - Bilthoven (NL) 4 National Centre for Rare Diseases - Rome (IT) The opinions expressed in this document are those of the Contractor only and do not represent the official position of the Executive Agency for Health and Consumers. This work is funded by the European Union with a grant of Euro 399755 (Contract number 2009 62 06 of the Executive Agency for Health and Consumers) 1 18/10/2011 Abbreviations 3hmg 3-Hydroxy-3-methylglutaric aciduria 3mcc 3-Methylcrotonyl-CoA carboxylase deficiency/3-Methylglutacon aciduria/2-methyl-3-OH- butyric aciduria AAD Disorders of amino acid metabolism arg Argininemia asa Argininosuccinic aciduria bio Biotinidase deficiency bkt Beta-ketothiolase deficiency btha S, beta 0-thalassemia cah Congenital adrenal hyperplasia cf Cystic fibrosis ch Primary congenital hypothyroidism citI Citrullinemia type I citII Citrullinemia type II cpt I Carnitin -
Sarcosine and Other Metabolites Along the Choline Oxidation Pathway in Relation to Prostate Cancer—A Large Nested Case–Control Study Within the JANUS Cohort in Norway
IJC International Journal of Cancer Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer—A large nested case–control study within the JANUS cohort in Norway Stefan de Vogel1, Arve Ulvik2, Klaus Meyer2, Per Magne Ueland3,4, Ottar Nyga˚rd5,6, Stein Emil Vollset1,7, Grethe S. Tell1, Jesse F. Gregory III8, Steinar Tretli9 and Tone Bjïrge1,7 1 Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway 2 BEVITAL AS, Bergen, Norway 3 Section for Pharmacology, Institute of Medicine, University of Bergen, Bergen, Norway 4 Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway 5 Section for Cardiology, Institute of Medicine, University of Bergen, Bergen, Norway 6 Department of Heart Disease, Haukeland University Hospital, Bergen, Norway 7 Norwegian Institute of Public Health, Bergen, Norway 8 Food Science and Human Nutrition Department, University of Florida, Gainesville, FL 9 The Cancer Registry of Norway, Oslo, Norway Methyl group donors and intermediates of one-carbon metabolism affect DNA synthesis and DNA methylation, and may thereby affect prostate carcinogenesis. Choline, the precursor of betaine, and the one-carbon metabolite sarcosine have been associated with increased prostate cancer risk. Within JANUS, a prospective cohort in Norway (n 5 317,000) with baseline serum samples, we conducted a nested case–control study among 3,000 prostate cancer cases and 3,000 controls. Using conditional logistic regression, odds ratios (ORs) and 95% confidence intervals (CIs) for prostate cancer risk were estimated according to quintiles of circulating betaine, dimethylglycine (DMG), sarcosine, glycine and serine. High sarcosine and glycine concentrations were associated with reduced prostate cancer risk of borderline significance (sarcosine: highest vs. -
What Disorders Are Screened for by the Newborn Screen?
What disorders are screened for by the newborn screen? Endocrine Disorders The endocrine system is important to regulate the hormones in our bodies. Hormones are special signals sent to various parts of the body. They control many things such as growth and development. The goal of newborn screening is to identify these babies early so that treatment can be started to keep them healthy. To learn more about these specific disorders please click on the name of the disorder below: English: Congenital Adrenal Hyperplasia Esapnol Hiperplasia Suprarrenal Congenital - - http://www.newbornscreening.info/Parents/otherdisorders/CAH.html - http://www.newbornscreening.info/spanish/parent/Other_disorder/CAH.html - Congenital Hypothyroidism (Hipotiroidismo Congénito) - http://www.newbornscreening.info/Parents/otherdisorders/CH.html - http://www.newbornscreening.info/spanish/parent/Other_disorder/CH.html Hematologic Conditions Hemoglobin is a special part of our red blood cells. It is important for carrying oxygen to the parts of the body where it is needed. When people have problems with their hemoglobin they can have intense pain, and they often get sick more than other children. Over time, the lack of oxygen to the body can cause damage to the organs. The goal of newborn screening is to identify babies with these conditions so that they can get early treatment to help keep them healthy. To learn more about these specific disorders click here (XXX). - Sickle Cell Anemia (Anemia de Célula Falciforme) - http://www.newbornscreening.info/Parents/otherdisorders/SCD.html - http://www.newbornscreening.info/spanish/parent/Other_disorder/SCD.html - SC Disease (See Previous Link) - Sickle Beta Thalassemia (See Previous Link) Enzyme Deficiencies Enzymes are special proteins in our body that allow for chemical reactions to take place. -
Proton NMR Spectroscopic Analysis of Multiple Acyl-Coa Dehydrogenase Deficiencyðcapacity of the Choline Oxidation Pathway for Methylation in Vivo
Biochimica et Biophysica Acta 1406Ž. 1998 274±282 View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Proton NMR spectroscopic analysis of multiple acyl-CoA dehydrogenase deficiencyÐcapacity of the choline oxidation pathway for methylation in vivo Shamus P. Burns a, Heather C. Holmes a, Ronald A. Chalmers c, Andrew Johnson b, Richard A. Iles a,) a Medical Unit, Cellular and Molecular Mechanisms Research Group, St. Bartholomew's and The Royal London School of Medicine and Dentistry, Whitechapel, London E1 1BB, UK b Biochemistry Unit, Institute of Child Health, London WC1N 1EH, UK c Paediatric Metabolism Unit, Department of Child Health, St. George's Hospital Medical School, London SW17 ORE, UK Received 20 January 1998; accepted 16 February 1998 Abstract Proton NMR spectra of urine from subjects with multiple acyl-CoA dehydrogenase deficiency, caused by defects in either the electron transport flavoprotein or electron transport flavoprotein ubiquinone oxidoreductase, provide a characteris- tic and possibly diagnostic metabolite profile. The detection of dimethylglycine and sarcosine, intermediates in the oxidative degradation of choline, should discriminate between multiple acyl-CoA dehydrogenase deficiency and related disorders involving fatty acid oxidation. The excretion rates of betaine, dimethylglycineŽ. and sarcosine in these subjects give an estimate of the minimum rates of both choline oxidation and methyl group release from betaine and reveal that the latter is comparable with the calculated total body methyl requirement in the human infant even when choline intake is very low. Our results provide a new insight into the rates of in vivo methylation in early human development. -
Overview of Newborn Screening for Organic Acidemias – for Parents
Overview of Newborn Screening for Organic Acidemias – For Parents What is newborn screening? What organic acidemias are on Indiana’s newborn screen? Before babies go home from the nursery, they have a Indiana’s newborn screen tests for several organic small amount of blood taken from their heel to test for acidemias. Some of the organic acidemias on a group of conditions, including organic acidemias. Indi ana’s newborn screen are: Babies who screen positive for an organic acidemia 3-Methylcrotonyl-CoA carboxylase need follow-up tests done to confirm they have the deficiency (also called 3-MCC deficiency) condition. Not all babies with a positive newborn Glutaric acidemia, type I screen will have an organic acidemia. Isovaleric acidemia Methylmalonic acidemia What are organic acidemias? Multiple-CoA carboxylase deficiency Propionic acidemia Organic acidemias are conditions that occur when a person’s body is not able to use protein to make What are the symptoms of organic acidemias? energy. Normally, when we eat, our bodies digest (or break down) food into certain proteins. Those Every child with an organic acidemia is different. proteins are used by our bodies to make energy. Most babies with organic acidemias will look normal Enzymes (special proteins that help our bodies at birth. Symptoms of organic acidemias can appear perform chemical reactions) usually help our bodies shortly after birth, or they may show up later in break down food and create energy. infancy or childhood. Common symptoms of organic A person with an organic acidemia is missing at least acidemias include weakness, vomiting, low blood one enzyme, or his/her enzymes do not work sugar, hypotonia (weak muscles), spasticity (muscle correctly. -
Original Article Prevalence of Aminoacidurias in a Tertiary Care Pediatric Medical College Hospital J
DOI: 10.14260/jemds/2015/650 ORIGINAL ARTICLE PREVALENCE OF AMINOACIDURIAS IN A TERTIARY CARE PEDIATRIC MEDICAL COLLEGE HOSPITAL J. N. George1, A. Amaresh2, N. J. Gokula Kumari3 HOW TO CITE THIS ARTICLE: J. N. George, A. Amaresh, N. J. Gokula Kumari. “Prevalence of Aminoacidurias in a Tertiary Care Pediatric Medical College Hospital”. Journal of Evolution of Medical and Dental Sciences 2015; Vol. 4, Issue 26, March 30; Page: 4500-4508, DOI: 10.14260/jemds/2015/650 ABSTRACT: BACKGROUND: Inborn errors of metabolism (IEM) comprises of a diverse group of heterogeneous disorders manifesting in paediatric population. Cases of Inborn errors of metabolism, individually are rare but collectively are common. The timing of presentation depends on significant accumulation of toxic metabolites or on the deficiency of substrate. These disorders manifest by subtle neurologic or psychiatric features often go undiagnosed until adulthood. OBJECTIVES: The objectives of the present study was to carry out preliminary screening on urine samples from pediatric population with either metabolic or neurological manifestations for inborn errors of metabolism and to know the prevalence of aminoaciduria in tertiary care setup for early diagnosis and detection. METHODS: The present study is a cross sectional time bound study carried out at Niloufer Institute of Child Health, Osmania Medical College, Hyderabad, from August 2013 to July 2014. A total of 119 samples were analyzed from suspected cases of IEM. Samples were analyzed for all physical and chemical parameters and positive cases reported by these investigations were referred for confirmation by TMS, HPLC, and GCMS. RESULTS: Among 119 children analyzed, 29 were given presumptive diagnosis of IEM based on screening tests, urinary aminoacidogram by TLC and clinical correlation. -
Pathological Findings in Homocystinuria
J Clin Pathol: first published as 10.1136/jcp.17.4.427 on 1 July 1964. Downloaded from J. clin. Path. (1964), 17, 427 Pathological findings in homocystinuria J. B. GIBSON', NINA A. J. CARSON, AND D. W. NEILL2 From the Departments ofPathology and of Child Health, and the Biochemistry Laboratory, The Queen's University of Belfast, and Royal Belfast Hospitalfor Sick Children, and Royal Victoria Hospital, Belfast SYNOPSIS Pathological findings are described in four cases of a new aminoaciduria in which homocystine is excreted in the urine. All the patients were mentally retarded children. Three of them presented diagnostic features of Marfan's syndrome. Necropsy on one case and biopsy findings in the others are described. Fatty change occurs in the liver. The most striking lesions are vascular. Metachromatic medial degeneration of the aorta and of the elastic arteries in the necropsied case are considered in relation to Marfan's syndrome. Other changes, particularly thrombosis which is prevalent in homocystinuria, suggest the possibility of a platelet defect. The findings are discussed in respect of an upset in the metabolism of sulphur-containing amino-acids and with particular reference to Marfan's syndrome. A systematic search for metabolic abnormalities in Their appearance was that of Marfan's syndrome mentally retarded individuals in Northern Ireland and in fact two of them had been designated pre- revealed a hitherto unrecognized specific amino- viously as classical examples of Marfan's syndrome aciduria, in which the sulphur-containing amino- in published studies of that condition (case A4, acid homocystine is excreted (Carson and Neill, Lynas, 1958; case 4, Loughridge, 1959). -
Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Birmingham, UK, 4 – 7 September 2012
J Inherit Metab Dis (2012) 35 (Suppl 1):S1–S182 DOI 10.1007/s10545-012-9512-z ABSTRACTS Annual Symposium of the Society for the Study of Inborn Errors of Metabolism Birmingham, UK, 4 – 7 September 2012 This supplement was not sponsored by outside commercial interests. It was funded entirely by the SSIEM. 01. Amino Acids and PKU O-002 NATURAL INHIBITORS OF CARNOSINASE (CN1) O-001 Peters V1 ,AdelmannK2 ,YardB2 , Klingbeil K1 ,SchmittCP1 , Zschocke J3 3-HYDROXYISOBUTYRIC ACID DEHYDROGENASE DEFICIENCY: 1Zentrum für Kinder- und Jugendmedizin de, Heidelberg, Germany IDENTIFICATION OF A NEW INBORN ERROR OF VALINE 2Universitätsklinik, Mannheim, Germany METABOLISM 3Humangenetik, Innsbruck, Austria Wanders RJA1 , Ruiter JPN1 , Loupatty F.1 , Ferdinandusse S.1 , Waterham HR1 , Pasquini E.1 Background: Carnosinase degrades histidine-containing dipeptides 1Div Metab Dis, Univ Child Hosp, Amsterdam, Netherlands such as carnosine and anserine which are known to have several protective functions, especially as antioxidant agents. We recently Background, Objectives: Until now only few patients with an established showed that low carnosinase activities protect from diabetic nephrop- defect in the valine degradation pathway have been identified. Known athy, probably due to higher histidine-dipeptide concentrations. We deficiencies include 3-hydroxyisobutyryl-CoA hydrolase deficiency and now characterized the carnosinase metabolism in children and identi- methylmalonic semialdehyde dehydrogenase (MMSADH) deficiency. On fied natural inhibitors of carnosinase. the other hand many patients with 3-hydroxyisobutyric aciduria have been Results: Whereas serum carnosinase activity and protein concentrations described with a presumed defect in the valine degradation pathway. To correlate in adults, children have lower carnosinase activity although pro- identify the enzymatic and molecular defect in a group of patients with 3- tein concentrations were within the same level as for adults.